Friday, February 03, 2023 12:53:34 AM
If you take what you stated regarding owning approx 65% of DMT as AGN/PF shareholder,,,the question remains how much of Moreau’s prancing peacock PR campaign is Algernon Neuroscience footing the bill? You think it’s OK to own 65% of something and pay 100% of the cost?
YES or NO?
The second topic being Christopher Moreau’s claim that the demonstrably failed COVID-19 Phase 2b “multinational” clinical trial had a 65% Chance Of Success...the question remains will Moreau begin spouting and shouting from pennyland rooftops the DMT program will have a 65% Chance Of Success at Phase 2? That’s assuming they will get beyond Phase 1 of the clinical trial process.
YES OR NO?
The same question can be asked of ANY of the drugs in the pipeline. When does the 55% and/or 65% Chance Of Success become the beating drunk of corporate officers in the know?
If there is any dispute regarding the above 65% number in the first and second instance, please try to address it specifically.
Meanwhile, I assume shell3 would have no dispute about Moreau’s BETTER THAN BACCARAT ODDS for Algernon Pharmaceuticals ``Repurposed Drugs' ' and Non Repurposed Drugs in its pipeline.
According to Algernon leadership...You Get A Car and You Get A Car...!!!
Here’s a post from shell3 (a longtime Moderator here) after observing one of the Biopub Webcasts during the height of the COVID-19 Pandemic:.
shell3 - Friday, February 28, 2020 12:41:10 PM
investorshub.advfn.com/boards/read_msg.aspx?message_id=154076718
Keep in mind, COVID-19 Clinical Trial Probability of Success statement(s) by the CEO and CFO on Biopub were BEFORE they had even filed paperwork with the FDA to begin the clinical trial process.
I Report.
You Decide.
Any Questions?
M$
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM